Nanoform
Financials
Estimates*
EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | <1m | 2.0m | 3.5m | 2.6m | 8.2m | 14.6m | 25.8m |
% growth | 1299 % | 185 % | 78 % | (26 %) | 220 % | 78 % | 76 % |
EBITDA | (18.2m) | (16.2m) | (18.9m) | (17.9m) | (14.9m) | (9.3m) | (9.1m) |
% EBITDA margin | (2647 %) | (829 %) | (541 %) | (697 %) | (181 %) | (64 %) | (35 %) |
Profit | (19.4m) | (19.7m) | (22.1m) | (20.8m) | (15.8m) | (12.8m) | (13.1m) |
% profit margin | (2831 %) | (1007 %) | (633 %) | (809 %) | (193 %) | (88 %) | (51 %) |
EV / revenue | 607.8x | 205.4x | 54.2x | 32.4x | 14.2x | 9.0x | 5.4x |
EV / EBITDA | -23.0x | -24.8x | -10.0x | -4.7x | -7.8x | -14.1x | -15.3x |
R&D budget | 1.4m | <1m | 1.0m | <1m | - | - | - |
R&D % of revenue | 198 % | 48 % | 29 % | 39 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Spinout | ||
N/A | $7.0m | Early VC | |
€10.0m | Early VC | ||
N/A | N/A | IPO | |
N/A | Grant | ||
* | N/A | €25.0m | Post IPO Equity |
* | €4.3m | Grant | |
Total Funding | CAD31.0m |
Related Content
Recent News about Nanoform
EditNanoform is a pioneering company in the field of nanotechnology and drug particle engineering, specializing in the creation of nanoparticles for the pharmaceutical industry. The company operates in the global healthcare market, serving pharmaceutical companies looking to enhance the effectiveness and targeting of their drugs. Nanoform's core business model revolves around its multi-patented Controlled Expansion of Supercritical Solutions (CESS) technology, which can produce pure and stable nanoparticles as small as 10 nanometers using supercritical carbon dioxide. This technology significantly increases the number of lead compounds progressing into clinical trials, thereby boosting the number of drugs that reach the market. Nanoform generates revenue by providing nanoforming services to its clients, helping them overcome drug development challenges and rapidly progress novel drugs to market. The company has received multiple accolades, including the CPhI Excellence in Pharma Award for Formulation and a Seal of Excellence from the European Commission.
Keywords: nanotechnology, drug particle engineering, pharmaceutical, nanoparticles, CESS technology, clinical trials, drug development, healthcare, innovation, supercritical carbon dioxide.